02 September 2022 | Friday | News
Image Source : Public Domain
Giorgio Calderari, Helsinn CEO commented: "I am pleased to announce this agreement with Juniper Biologics today which further widens the geographic distribution of LEDAGA® making this treatment option available to even more patients suffering from MF-CTCL. Juniper Biologics is an excellent partner for Helsinn and I'm looking forward to working with them to deliver on our mission to improve the lives of people with cancer all over the world."
Raman Singh, CEO of Juniper Biologics stated: "This latest deal is testament of the shared purpose and strong partnership between Juniper Biologics and the Helsinn Group. The licensing of LEDAGA® marks a key milestone in our mission to help improve the treatment for patients suffering from the burden of MF-CTCL. With LEDAGA®, we will not only be adding to our growing portfolio of oncology medicines, we will more importantly be providing cancer patients with access to this important treatment option."
Chlormethine gel 0.016%, also known as mechlorethamine gel, is approved in multiple countries, including the EU and US, and is marketed under the trade names LEDAGA® and VALCHLOR®. The authorized use for each country varies based on the design of the registrational trial and the individual health authority requirements. For more details, please refer to the approved product information for each respective jurisdiction.
*The full list of countries and regions covered by the license agreement includes: Australia, Afghanistan, Armenia, Azerbaijan, Bangladesh, Bhutan, Brunei, Cambodia, Georgia, India, Indonesia, Iraq, Kazakhstan, Kyrgyzstan, Laos, Malaysia, Mongolia, Myanmar, Nepal, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Tajikistan, Turkmenistan, Uzbekistan and Vietnam.